Article
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Clinical pharmacology and therapeutics - 1 Aug 2021
Ahamadi Malidi, Mehrotra Nitin, Hanan Nathan, Lai Yee Ka, Gheyas Ferdous, Anton Judith, Bani Massimo, Boroojerdi Babak, Smit Hans, Weidemann Jonas, Macha Sreeraj, Thuillier Vincent, Chen Chao, Yang Minhua, Williams-Gray Caroline H, Stebbins Glenn T, Pagano Gennaro, Hang Yaming, Marek Kenneth, Venuto Charles S, Javidnia Monica, Dexter David, Pedata Anne, Stafford Bob, Akalu Mussie, Stephenson Diane, Romero Klaus, Sinha Vikram
Abstract excerpt
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and nonmotor features is particularly important in assessing the potential therapeutic effect of LRRK2 inhibitors in clinical development. Using standardized data from the Critical Path for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.